| Date | Title | Description |
| 14.11.2024 | Metsera Raises $215M in Series B Financing | Metsera, a NYC-based clinical-stage biopharmaceutical company, raised $215M in Series B funding.
The round was led by Wellington Management and Venrock, with participation from Fidelity Management and Research Company, Janus Henderson Inves... |
| 13.11.2024 | Trace Neuroscience: A New Dawn in Genomic Medicine for ALS | In the realm of biopharmaceuticals, a new player has emerged, armed with ambition and a hefty $101 million in Series A funding. Trace Neuroscience is on a mission to reshape the landscape of genomic medicine, particularly for those grapplin... |
| 13.11.2024 | Alentis Therapeutics Secures $181.4 Million to Pioneer Cancer Treatments | In a bold move to reshape cancer treatment, Alentis Therapeutics has successfully raised $181.4 million in an oversubscribed Series D funding round. This infusion of capital, led by OrbiMed and co-led by Novo Holdings and Jeito Capital, sig... |
| 13.11.2024 | Alentis Therapeutics: $181.4 Million (Series D) Raised To Develop Treatments For Claudin-1 Tumors | Alentis Therapeutics – a clinical-stage biotechnology company developing treatments for Claudin-1 positive (CLDN1+) tumors and organ fibrosis – announced that it has raised $181.4 million in Series D funding, supported by a syndicate of top... |
| 13.11.2024 | Trace Neuroscience: $101 Million (Series A) Raised To Expand Genomic Medicine Platform | Trace Neuroscience – a biopharmaceutical company expanding the promise of genomic medicine for people living with neurodegenerative diseases – announced its launch with a $101 million Series A funding led by Third Rock Ventures, with partic... |
| 12.11.2024 | Alentis Therapeutics raises $181.4 million in oversubscribed series D round | Normal 0 false false false EN-GB X-NONE AR-SA
Besides OrbiMed, Novo Holdings and Jeito Capital, Alentis Therapeutics’ series D round saw the participation of new investors Frazier Life Sciences, Longitude Capital, Catalio Capital, Piper Hea... |
| 28.10.2024 | Be Biopharma: Pioneering the Future of Genetic Medicine with $82 Million in New Funding | In the ever-evolving landscape of biotechnology, Be Biopharma stands out like a lighthouse in a storm. This Cambridge, Massachusetts-based company has just secured $82 million in funding, a financial windfall that promises to propel its inn... |
| 25.10.2024 | Be Bio: $82 Million Raised To Discover And Develop Engineered B Cell Medicines | Be Biopharma – a leader in the discovery and development of engineered B Cell Medicines (BCMs) – announced key milestones alongside a new round of funding as its lead program BE-101 for Hemophilia B, enters the clinic, and its second develo... |
| 23.10.2024 | Alpha-9 Oncology Raises $175M in Series C Financing | Alpha-9 Oncology Inc., a Boston, MA- and Vancouver, Canada-based clinical stage company developing radiopharmaceuticals to meaningfully improve the treatment of people living with cancer, raised $175m in Series C financing.
The round was le... |
| 03.09.2024 | Vesta Healthcare Receives 35M Loan Facility From Horizon Technology Finance | Vesta Healthcare (aka Hometeam Technologies, Inc.), a NYC-based tech-enabled clinical services company, receivded a $35M venture loan facility from Horizon Technology Finance (NASDAQ: HRZN).
A $25M portion has been initially funded.
The com... |
| 26.08.2024 | Opna Bio Doses First Patient in Phase 1 Study in Multiple Myeloma with OPN-6602, an EP300/CBP Bromodomain Inhibitor | Appoints Axel Bolte, MBA, MSc, to Board Director and Stephanie Oestreich, PhD, MPA, to Board Observer
SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–August 26, 2024–
Opna Bio announced that it has dosed the first patient with OPN-6602, a poten... |
| 03.08.2024 | Outpace Bio: A New Dawn in Cancer Treatment with AI-Powered Cell Therapies | In the realm of cancer treatment, innovation is the lifeblood. Outpace Bio is injecting fresh vigor into this field with its recent $144 million Series B financing. This funding, led by RA Capital Management, is a beacon of hope for patient... |
| 01.08.2024 | Outpace Bio Secures $144M for AI-Powered Cell Therapy Platform | What You Should Know:
– Outpace Bio, a pioneering cell therapy company raises $144M in oversubscribed Series B financing round led by RA Capital Management with participation from both new and existing investors, including Qatar Investment ... |
| 28.07.2024 | The Surge of Innovation: How Magenta Medical and Brenig Therapeutics are Shaping the Future of Healthcare | In the world of healthcare, innovation is the lifeblood that keeps the industry thriving. Two companies, Magenta Medical and Brenig Therapeutics, are at the forefront of this revolution. With significant funding rounds recently completed, t... |
| 26.07.2024 | Magenta Medical: Heart Pump Company Raises $105 Million | Magenta Medical, the developer of Elevate (the world’s smallest heart pump), announced it had closed a $105 million funding round led by global healthcare investment firm Novo Holdings. The new investors Viking Global Investors and RA Capit... |
| 17.06.2024 | Bright Peak Therapeutics raises USD90 million to advance lead program into clinical trials |
Bright Peak Therapeutics is a biotechnology company advancing a portfolio of multifunctional immunotherapies to treat cancer and other diseases. “We are now well positioned to bring much needed innovation to the field of anti-PD-1 immune-c... |
| 23.05.2024 | Venture Leaders Biotech 2024: Captains Blog by Maria Van Dongen, CEO of Allegria Therapeutics, and Gabriel Liguori, CEO of TissueLabs | Venture Leaders Biotech 2024: Captains Blog by Maria Van Dongen, CEO of Allegria Therapeutics, and Gabriel Liguori, CEO of TissueLabs 23.05.2024 12:30, Rita Longobardi linkedIn facebook twitter instagram youtube -->
In mid-May, the ten V... |
| 02.05.2024 | Forbion Portfolio Company Mariana Oncology to be Acquired by Novartis to Advance Precision Radiopharmaceuticals to Treat Cancer | • Latest deal marks the fifth Forbion portfolio company to be acquired for over $1 bn within a year
Naarden, The Netherlands, 2 May 2024 - Forbion portfolio company Mariana Oncology (Mariana) is to be acquired by Novartis for $1 billion in ... |
| 27.02.2024 | Freenome scores $254M to advance its cancer-detection blood tests | The San Francisco company readies to reveal its first clinical study results in the near term
When it comes to cancer, spotting it early can make a big difference on treatment options and survival. Commonly a progressive disease, certain un... |
| 20.02.2024 | Freenome's $254M Boost for Early Cancer Detection | Freenome, a biotech company in San Francisco, just secured a massive $254M in funding to advance their blood-based cancer detection tests. The investment, led by Roche and backed by a slew of other big names, will propel Freenome's mission ... |
| 15.02.2024 | Freenome Raises $254M to Accelerate Early Cancer Detection Platform | What You Should Know:
– Freenome, a leader in blood-based early cancer detection, has raised $254M in a new funding round, fueled by its innovative multiomics platform and promising pipeline of tests. The funding was led by Roche with parti... |
| 16.01.2024 | Vaxart Announces $10.0 Million Registered Direct Offering with RA Capital Management | - |
| 17.10.2023 | Ventricle Health Secures $8M to Accelerate Value-Based Home Care Model for Heart Failure | What You Should Know:
– Ventricle Health – a new national, virtual cardiology clinical reimagining cardiac care delivery – raises $8M in seed funding led by RA Capital and Waterline Ventures.
– This company will used the seed funding to exp... |
| 10.07.2023 | SpyGlass Pharma Completes $90 Million Series C Financing to Advance Novel Treatments for Glaucoma and other Chronic Ophthalmic Diseases | www.spyglasspharma.com
ALISO VIEJO, Calif. (PRWEB) July 10, 2023
SpyGlass Pharma, a privately-held ophthalmic therapeutics company, announced today closing $90 million in Series C financing. The financing, which was led by RA Capital Manage... |
| 25.05.2023 | The Week in AgriFoodTech: Pluton Biosciences bags $16.5m, Babylon Micro-Farms secures funds, José Andrés launches climate institute | This week, agtech companies Pluton Biosciences and Babylon Micro-Farms raised funds for microbial cover crops and vertical farms, respectively. Celebrity chef José Andrés teamed up with a university for a new food and climate institute, and... |
| 13.04.2023 | Alentis Therapeutics closes USD 105 million Series C round | |
| 12.03.2023 | RA Capital Urges Swift Federal Response to SVB Crisis | BOSTON, March 12, 2023 /PRNewswire/ -- RA Capital Management, LP ("RA Capital") today issued the following letter urging Biden Administration officials and Congressional leaders to quickly and clearly assure the depositors of Sili... |
| 13.04.2022 | CDR-Life Closes $76 million Series A Funding | |
| 18.11.2021 | VC Daily: RA Capital Launches Biotech Startup Avilar Therapeutics With $60 Million | Good day. Healthcare investor RA Capital Management has launched and invested $60 million in Avilar Therapeutics Inc., a biotechnology startup seeking to expand the emerging field of protein degradation.
Existing drugs typically block disea... |
| 07.10.2021 | Who beat out Tiger Global as the most active venture investor of the third quarter? | This is the web version of Term Sheet, a daily newsletter on the biggest deals and dealmakers. Sign up to get it delivered free to your inbox.
Hedge fund giant Tiger Global turned itself into the 800-pound gorilla of venture capital deals i... |
| 06.10.2021 | RA Capital Management, LP Closes $880 Million Venture Capital Fund | BOSTON, Oct. 06, 2021 (GLOBE NEWSWIRE) -- RA Capital Management, LP (“RA Capital”) has held a first and final closing of its third venture fund, RA Capital Nexus Fund III, L.P. (“Nexus III”). Significantly oversubscribed, Nexus III successf... |
| 06.10.2021 | RA Capital Management, LP Closes $880 Million Venture Capital Fund | BOSTON, Oct. 06, 2021 (GLOBE NEWSWIRE) -- RA Capital Management, LP (“RA Capital”) has held a first and final closing of its third venture fund, RA Capital Nexus Fund III, L.P. (“Nexus III”). Significantly oversubscribed, Nexus III successf... |
| 29.07.2021 | Exo Raises $220M to Commercialize Handheld, Point-of-Care Ultrasound Device | What You Should Know:
– Exo (pronounced “echo”), a pioneering health information and devices company, announced it has raised $220M in Series C investment round led by RA Capital Management and joined by BlackRock, Sands Capital, Avidity Pa... |
| 14.06.2021 | Bright Peak Therapeutics Closes $107 Million Financing Round | |
| 24.05.2021 | Eliem Therapeutics, Inc. announced that it has received $60 million in funding from Intermediate Capital Group plc, RA Capital Management, L.P., Access Biotechnology, Samlyn Capital, LLC, Acorn Bioven... | On May 24, 2021, Eliem Therapeutics, Inc. closed the transaction. The company announced that it has received $60,000,000 in its series B round of funding co-led by returning investors RA Capital Management, L.P. and Intermediate Capital Gro... |
| 29.04.2021 | Ysios Capital leads a €51M round in Adcendo, also followed up by Novo Seeds, RA Capital Management, HealthCap and Gilde | ADCENDO RAISES €51 MILLION IN SERIES A FINANCING TO ADVANCE NOVEL ANTIBODY-DRUG CONJUGATES FOR TREATMENT OF CANCERS.
Financing led by Novo Seeds and Ysios Capital is largest Series A for a Danish biotech company
Plans to build a pipeline o... |
| 29.04.2021 | Ysios Capital lidera una inversión de €51 millones en Adcendo. Acuden también Novo Seeds, RA Capital Management, HealthCap y Gilde | 29/04/2021
Nota de prensa
YSIOS CAPITAL LIDERA UNA INVERSIÓN DE €51 MILLONES EN ADCENDO.
− Adcendo (Copenhague, Dinamarca), es una compañía biotecnológica especializada en el desarrollo de fármacos inmunoconjugados para el tratamiento de... |
| 20.04.2021 | RA Capital leads $125M for Janux in VC's latest crossover bid | Four months ago, only a short list of people had ever heard of Janux Therapeutics. Today, they have a partnership with Merck, $212 million in VC capital and, it seems, plans for an IPO.
Janux announced Tuesday a $125 million ... |
| 31.03.2021 | New Equilibrium Bio raises $10 Million from RA Capital for AI-powered Quantum Chemistry | New Equilibrium, the pioneer in rational drug design against intrinsically disordered proteins (IDPs), has closed a $10 million seed from RA Capital Management. New Equilibrium’s platform reveals previously-undetectable opportunities for st... |
| 17.03.2021 | Research Alliance Corp. II, Sponsored by RA Capital Management, L.P., Announces Pricing of $130 Million Initial Public Offering | LAS VEGAS--(BUSINESS WIRE)--Mar 17, 2021--
Research Alliance Corp. II (the “Company”) announced today that it priced its initial public offering of 13,000,000 shares of Class A common stock at $10.00 per share. The shares will be listed on ... |
| 09.12.2020 | RA Capital Management Leads $45M Series A Financing for PepGen's Next-Generation Oligonucleotide Platform Targeting Duchenne Muscular Dystrophy and Other Rare Neuromuscular and Cardiac Diseases | BOSTON and OXFORD, United Kingdom, Dec. 09, 2020 (GLOBE NEWSWIRE) -- PepGen, a therapeutics company targeting severe neuromuscular diseases, including Duchenne muscular dystrophy (DMD), has closed a $45 million Series A funding round led by... |
| 21.10.2020 | RA Capital raises $461m for fund | - |
| 21.10.2020 | RA Capital Management Raises $461 Million | BOSTON, Oct. 21, 2020 (GLOBE NEWSWIRE) -- RA Capital Management, LP has held a first and final closing of its second venture fund, RA Capital Nexus Fund II, L.P., raising $461 million.
“We deeply appreciate the continued support of our exis... |
| 21.10.2020 | RA Capital Management Raises $461 Million | BOSTON, Oct. 21, 2020 (GLOBE NEWSWIRE) -- RA Capital Management, LP has held a first and final closing of its second venture fund, RA Capital Nexus Fund II, L.P., raising $461 million.
“We deeply appreciate the continued support of our exis... |
| 25.08.2020 | Connect Biopharma closes $115m in Series C round led by RA Capital | Premium
US and China-based clinical-stage biopharmaceutical firm Connect Biopharma on Monday announced the completion of a $115-million Series C round of financing led by new investor RA Capital Management, a Boston-based multi-stage invest... |
| 06.08.2020 | Aerovate Therapeutics Emerges From RA Capital Incubator With $72.6 Million Funding | BOSTON, Aug. 06, 2020 (GLOBE NEWSWIRE) -- Aerovate Therapeutics, Inc., has closed on $72.6 million in Series A funding to advance trials of AV-101, an inhaled, dry powder aerosol version of imatinib to treat pulmonary arterial hypertension ... |
| 05.08.2020 | GentiBio Launches with $20M Seed Funding from OrbiMed, Novartis Venture Fund and RA Capital Management, L.P. to Develop Engineered Regulatory T cells to Deliver Immune Tolerizing Therapies for Autoimm... | - |
| 26.03.2020 | SutroVax Announces $110M Series D Financing to Advance Broadest-Spectrum Pneumococcal Vaccine Candidates to Prevent Pneumonia | Foster City, CA, March 26, 2020 – SutroVax, a biopharmaceutical company dedicated to the delivery of superior and novel vaccines designed to prevent or treat some of the most common and deadly infectious diseases worldwide, today announced ... |
| 18.07.2019 | RA Capital Management Closes First Venture Fund At Over $300 Million | RA Capital Management has closed its first and inaugural venture fund called RA Capital Nexus Fund, L.P. (“Nexus”) at just over $300 million
RA Capital Management has officially closed its first and inaugural venture fund called RA Capital ... |
| 15.07.2019 | RA Capital Raises $308M Venture-capital Fund | RA Capital Management said it has raised a venture-capital fund of $308 million to target life sciences investing, according to a filing with the SEC.
The Boston-based firm said the new fund boosts private company deal capacity to about $1 ... |
| 15.07.2019 | RA Capital Management Closes First Fund, at Over $300M | RA Capital Management, LLC, a Boston, MA-based venture capital firm, closed its inaugural fund, at just over $300m.
RA Capital Nexus Fund, L.P., which boosts RA Capital’s private deal capacity to nearly $1 billion and total assets under man... |
| 15.07.2019 | RA Capital Management closes $308M venture capital fund | In a Form D posted Friday on the Securities and Exchange Commission website, the firm stated that the total amount sold was $308.15 million, domiciled in the U.S. Another Form D was posted on the SEC site the same day, for “RA Capital Nexus... |
| 15.07.2019 | RA Capital Raises $308M Venture-capital Fund | RA Capital Management said it has raised a venture-capital fund of $308 million to target life sciences investing, according to a filing with the SEC.
The Boston-based firm said the new fund boosts private company deal capacity to about $1 ... |
| 11.06.2018 | In the heart of one of the biggest Life Sciences hubs - tales from a Swiss entrepreneur in Boston | In the heart of one of the biggest Life Sciences hubs - tales from a Swiss entrepreneur in Boston 11.06.2018 09:00, Charlotte Pichon linkedIn facebook twitter instagram youtube -->
Venture Leaders Life Sciences team member Mathieu Horras... |
| 10.01.2017 | Singapore: EDBI & Vertex Ventures-backed Ivantis closes $25m Series C | Premium
Ivantis Inc., developer of the Hydrus Microstent device designed to lower eye pressure for glaucoma patients, has closed a $25 million Series C financing round led by new investor RA Capital Management. The round also included new i... |
| 09.01.2017 | RA Capital Leads $25M Series C for Ivantis | Ivantis Inc., developer of the novel Hydrus™ Microstent device designed to lower eye pressure for glaucoma patients, announced today that it closed a $25 million Series C financing. The round was led by new investor RA Capital Management, a... |
| 08.01.2017 | RA Capital Leads $12M Series A for Satsuma Pharmaceuticals | Satsuma Pharmaceuticals, Inc., a leader in developing best-in-class therapies to address the unmet needs of migraine sufferers, announced the closing of a $12 million Series A financing co-led by RA Capital Management and TPG Biotech. RA Ca... |
| 05.01.2017 | AgriMetis Raises $23.5m Series B for Natural Products-Derived Crop Protection Research – exclusive | AgriMetis, the crop protection spin-off from healthcare innovation firm Acidophil, has raised $23.5 million in Series B funding in an oversubscribed round led by Anterra Capital.
Joining the round and making a crossover investment from the ... |
| 20.07.2016 | RA Capital Leads $10M Series B for Synthorx | Synthorx Inc. announced today the completion of a $10 million Series B financing, led by RA Capital Management and joined by Series A investors Avalon Ventures and Correlation Ventures. In conjunction with the financing, Andrew Levin, M.D.,... |
| 20.07.2016 | Synthorx receives $10M to pivot toward treatments | The influx of capital will fund a significant evolution at Synthorx, which has been focused on validating their synthetic biology technology. The additional resources will allow them to begin developing treatments, pivoting from a platform ... |
| 29.10.2015 | Daily funding roundup - October 29, 2015 | Brandwatch completed $33M funding; Qvella raised $20M; Gobble landed $10.75M
Mangatar, a Milan, and Salerno, Italy-based social and mobile gaming startup, raised €1.1 million ($1.2 million) in funding. The funds were raised via Fi.R.A. (Fin... |
| 27.10.2015 | Daily funding roundup - October 27, 2015 | Taris Biomedical raised $32M; SimilarWeb scored $25M; Spigit secured $13M
Real-time consumer engagement app OnePulse has closed a $1.07 million seed investment round, led by AngelLab, D5 Capital and the London Co-Investment Fund along with ... |
| 21.10.2015 | Daily funding roundup - October 21, 2015` | Arvinas bagged $41.6M; Clavis Insight received $20M; Adjust landed $17M
LeanTaaS, a Silicon Valley healthcare SaaS provider, today announced its first institutional funding round of $3 million led by Sedgwick Claims Management Services, Inc... |
| 06.10.2015 | RA Capital Advisors Closes $425 Million Acquisition | San Diego-based investment bank RA Capital Advisors on Tuesday announced pest control giant Rentokil Initial plc bought RA client Steritech Group Inc. for $425 million, which it said was the largest acquisition in the pest control industry.... |
| 09.09.2015 | Daily funding roundup - September 9, 2015 | Didi Kuaidi scored $1B; Chef bagged $40M; Primus Power raised $25M
The battle for supremacy among e-hailing services in China is heating up, and fast. In the same week that Uber revealed that it has raised an additional $1.2 billion to expa... |
| 24.07.2015 | Daily funding roundup - July 24, 2015 | Northleaf Venture Catalyst Fund closed $300M; Voxel8 received $12M; AdAgility raised $1.6M
AdAgility, a provider of personalized, on-site and mobile, cross-selling solutions, raised $1.6 million to further accelerate its already impressive ... |
| 22.07.2015 | Daily funding roundup - July 22, 2015 | Events.com has now raised a total of $17M; Darktrace landed $22.5M; Kinetic Social closed $17.5M
Events.com has raised a new round of funding. The size of the round was undisclosed, but it was led by Arctaris and with participation from La ... |
| 19.07.2015 | Easy pill to swallow: Aussie biotech startup raises $40 million in funding round | A biotech startup spun out of the University of Queensland has raised $40 million to help develop a drug, which may make injection-based treatments for some gastrointestinal diseases and disorders obsolete.
Protagonist Therapeutics, a US in... |
| 17.07.2015 | Daily funding roundup - July 17, 2015 | Protagonist Therapeutics bagged $40M; Upstart raised $35M; Courtagen secured $20M
CredSimple, a startup building a medical credentialing database, snagged $1.5 million in seed funding to help healthcare and insurance companies manage their ... |
| 22.07.2014 | MoneyTree Reports $121M in MI Venture Deals Last Quarter | Share Share on Facebook Share on Twitter LinkedIn Email Reprints
Venture Capital investors had a very active second quarter of 2014, according to the latest MoneyTree report. VCs invested almost $13 billion in 1,114 U.S. startups during the... |
| 22.04.2014 | ProNAi Therapeutics Closes on $59.5M to Advance Cancer Drug | Share Share on Facebook Share on Twitter LinkedIn Email Reprints
ProNAi Therapeutics, a Plymouth, MI-based developer of novel nucleic acid treatments targeting cancer and other genetic diseases, said this week that it has closed a Series D ... |
| 21.04.2014 | ProNAi raises $60 million to advance treatment to combat lymphoma | Among the applications for its PNT2258 treatment are diffuse large B-cell lymphoma, Richter’s transformation, and follicular lymphoma. The funds will also support drug manufacturing, advance development of preclinical drug candidates and th... |
| 27.07.2012 | Fundraising: Gene therapy firm targeting sickle cell anemia raises $60M | Product: Gene therapy to target sickle cell anemia, beta-thalassemia and childhood cerebral adrenoleukodystrophy
Money raised: $60 million in series D; at least $76 million in previous rounds based on press releases and U.S. Securities and ... |
| 12.06.2007 | Cleveland biotech Athersys raises $65M with reverse-merger | Athersys, a Cleveland, Ohio biotech, went public via reverse merger and raised $65 million in a private placement. The company’s release is here.
Founded in 1995, Athersys is active in a bewildering number of areas. Its lead product candida... |
| - | Adcendo raises EUR 51 Million in Series A Financing to Advance Novel Antibody-Drug Conjugates for Treatment of Cancers | Copenhagen, Denmark, 29 April 2021 – Adcendo, a biotech company developing antibody-drug conjugates (ADCs) for the treatment of cancers, today announced the successful closing of a EUR 51 million (US$ 62 million) Series A financing. The inv... |
| - | Research Alliance Corp. II, Sponsored by RA Capital Management, L.P., Announces Closing of $149.5 Million Initial Public Offering, Including the Full Exercise of the Underwriter’s Option to Purchase A... | LAS VEGAS--(BUSINESS WIRE)--Mar 22, 2021--
Research Alliance Corp. II (Nasdaq:RACB) (the “Company”) announced today that on March 22, 2021 it closed its initial public offering of 14,950,000 shares of Class A common stock, including 1,950,0... |
| - | Successful closing of a US$ 55M Series A financing | Copenhagen, Denmark and Boston, US – 22 July 2021
Hemab ApS (“Hemab”), a biotech company developing next generation therapeutics for serious underserved bleeding and thrombosis disorders, today announces the successful closing of a US$ 55M... |
| - | Synthorx receives $10M to pivot toward treatments | Synthorx, a synthetic biology company based in San Diego, has received $10 million in series B financing.
The company will use the money to ramp up efforts to develop advanced protein therapeutics based on its synthetic amino acid platform.... |
| - | Fundraising: Gene therapy firm targeting sickle cell anemia raises $60M | Company name: bluebird bio.
Industry: Biotechnology.
Location: Cambridge, Massachusetts.
Product: Gene therapy to target sickle cell anemia, beta-thalassemia and childhood cerebral adrenoleukodystrophy
Money raised: $60 million in series D;... |
| - | ProNAi raises $60 million to advance treatment to combat lymphoma | Cancer drug developer ProNAi Therapeutics, which developed a nucleic acid-based DNA-interference technology to cause cancer cell death, has added nine new investors in an oversubscribed Series D round.
The latest fundraise will help support... |
